B-cell Inhibitors Market for Non-Oncology Diseases: Industry Trends and Global Forecasts, Till 2035 - Distribution by Stage of Development, Indication and Key Geographies
Description
B-CELL INHIBITORS MARKET FOR NON-ONCOLOGY DISEASES: OVERVIEW
As per Roots Analysis, the B-cell inhibitors market for non-oncology diseases is estimated to grow from USD 21.2 billion in the current year to USD 51.5 billion by 2035, at a CAGR of 9.30% during the forecast period, till 2035.
B-cell Inhibitors Market for Non-Oncology Diseases
The market sizing and opportunity analysis has been segmented across the following parameters:
Stage of Development
B-cell inhibitors are essential for regulating immune responses and are used in treating autoimmune diseases and B-cell malignancies. Significantly, B cell inhibitors function by targeting B cells through various mechanisms. Monoclonal antibodies that target B-cell surface markers such as CD20 and CD19 interfere with survival signals, whereas small molecule inhibitors, such as Bruton’s tyrosine kinase disrupt B-cell receptor signaling pathways, thus hindering B-cell activation, proliferation, and survival. These treatments have demonstrated wide-ranging effectiveness in addressing issues such as lymphomas, chronic lymphocytic leukemia, multiple sclerosis, and lupus. Currently, more than 400 B-cell inhibitors are at various phases of clinical testing for non-oncology diseases. Further, the industry has witnessed notable investments and strategic partnerships due to its ability to overcome current production constraints and enhance therapeutic results. Consequently, such developments highlight the increasing focus towards tackling unfulfilled medical requirements. B-cell inhibitors are expected to see significant growth, positioning them as critical enablers of the next generation of genetic medicines.
The market for B-cell inhibitors is expanding due to the increasing occurrence of autoimmune diseases, such as rheumatoid arthritis and lupus, as well as blood cancers, including non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, and diffuse large B-cell lymphoma. Additionally, the rising need for targeted immunomodulatory therapies that have fewer side effects than conventional treatments is driving investment and innovation in this field.
B-CELL INHIBITORS MARKET FOR NON-ONCOLOGY DISEASES: KEY INSIGHTS
The report delves into the current state of the B-cell inhibitors market for non-oncology diseases and identifies potential growth opportunities within industry. Some key findings from the report include:
1. The current market landscape is fragmented, featuring the presence of both established players and new entrants; of these, 36% of B-Cell inhibitors are being developed by very large companies.
2. Majority of the B cell inhibitors are presently being evaluated under phase II of clinical development; 50% of the inhibitors can be administered orally.
3. A decent increase in the number of registered clinical trials has been observed in recent years; most of the trials evaluating B-cell inhibitors have been sponsored by industry players.
4. The patent filing activity suggests that various industry and non-industry players are striving to safeguard their innovations within the B-cell inhibitors domain.
5. The rising interest in this domain is also reflected by the number of partnerships that have been inked in the recent past, involving both international and local stakeholders.
6. Assessment of the key drivers and barriers in the B-cell inhibitors market provides valuable insights to stakeholders, allowing them to enhance their offerings to adapt to the evolving needs.
7. The overall opportunity within B-cell inhibitors market is anticipated to be well distributed across various key geographies, stage of development and indication.
8. The B-cell inhibitors market in North America is expected to capture maximum share in the current year; further, close to 60% of the companies in this domain are offering inhibitors for multiple sclerosis.
9. Driven by the rising prevalence of autoimmune disorders and focus on targeted therapy development, the B-cell inhibitors market in the US is expected to grow at CAGR of 9.0%, during the forecast period.
B -CELL INHIBITORS MARKET FOR NON-ONCOLOGY DISEASES: KEY SEGMENTS
Marketed Sub-Segment Holds the Largest Market Share in the B-cell Inhibitors Market for Non-oncology Diseases
In terms of stage of development, the B-cell inhibitors market for non-oncology diseases is distributed across phase II, phase III and marketed. In the current year, the marketed sub-segment occupies the highest market share (over 80%), owing to the strong presence of B-cell Inhibitors, such as rituximab and ibrutinib. These inhibitors are known to cater to multiple indications, thus leading to expansion in their market reach. The market for B-cell Inhibitors in phase III is likely to witness a significant growth rate (CAGR) of 43% during the forecast period. This is because of the rising prevalence of autoimmune disorders across different countries.
Multiple Sclerosis Sub-Segment Holds the Largest B-cell Inhibitors Market for Non-oncology Diseases Share
In terms of indication, the B-cell inhibitors market for non-oncology diseases is distributed across ANCA, Graves' disease, hidradenitis suppurativa, immune thrombocytopenia, immunoglobulin nephropathy, membranous nephropathy, multiple sclerosis, myasthenia gravis, neuromyelitis optica, rheumatoid arthritis, sickle cell anemia, systemic lupus erythematosus, warm autoimmune hemolytic anemia. In the current year, the multiple sclerosis sub-segment holds the largest market share. This is due to the fact that multiple inhibitors have received approval for this indication across different regions. Some of these approved drugs include alemtuzumab, baricitinib, belimumab and ocrelizumab. Further, we anticipate the market to witness a substantial increase in the share of immunoglobulin nephropathy sub-segment, growing at a CAGR of 34% during the forecast period. This is because several B-cell Inhibitors are currently in the later stages of development and are likely to receive approval in the coming year.
North America Constitutes the Largest B-cell Inhibitors Market for Non-oncology Diseases Share
According to the B-cell inhibitors market for non-oncology diseases share analysis, North America is likely to capture the majority (~75%) of the B-cell Inhibitors Market for Non-oncology Diseases share in the current year. This is because North America has developed advanced healthcare infrastructure that allows developers to carry out extensive clinical trials to collect data for regulatory approval. It is worth highlighting that the market in China is likely to have higher B-cell Inhibitors Market for Non-oncology Diseases growth rate (15%). This is due to the rapidly growing patient population, the rising incidence of various indications in this country.
Example Players in the B-cell Inhibitors Market for Non-oncology Diseases
As per Roots Analysis, the B-cell inhibitors market for non-oncology diseases is estimated to grow from USD 21.2 billion in the current year to USD 51.5 billion by 2035, at a CAGR of 9.30% during the forecast period, till 2035.
B-cell Inhibitors Market for Non-Oncology Diseases
The market sizing and opportunity analysis has been segmented across the following parameters:
Stage of Development
- Phase II
- Phase III
- Marketed
- ANCA
- Graves' Disease
- Hidradenitis Suppurativa
- Immune Thrombocytopenia
- Immunoglobulin Nephropathy
- Membranous Nephropathy
- Multiple Sclerosis
- Myasthenia Gravis
- Neuromyelitis Optica
- Rheumatoid Arthritis
- Sickle Cell Anemia
- Systemic Lupus Erythematosus
- Warm Autoimmune Hemolytic Anemia
- North America
- Europe
- Asia-Pacific and Rest of the World
B-cell inhibitors are essential for regulating immune responses and are used in treating autoimmune diseases and B-cell malignancies. Significantly, B cell inhibitors function by targeting B cells through various mechanisms. Monoclonal antibodies that target B-cell surface markers such as CD20 and CD19 interfere with survival signals, whereas small molecule inhibitors, such as Bruton’s tyrosine kinase disrupt B-cell receptor signaling pathways, thus hindering B-cell activation, proliferation, and survival. These treatments have demonstrated wide-ranging effectiveness in addressing issues such as lymphomas, chronic lymphocytic leukemia, multiple sclerosis, and lupus. Currently, more than 400 B-cell inhibitors are at various phases of clinical testing for non-oncology diseases. Further, the industry has witnessed notable investments and strategic partnerships due to its ability to overcome current production constraints and enhance therapeutic results. Consequently, such developments highlight the increasing focus towards tackling unfulfilled medical requirements. B-cell inhibitors are expected to see significant growth, positioning them as critical enablers of the next generation of genetic medicines.
The market for B-cell inhibitors is expanding due to the increasing occurrence of autoimmune diseases, such as rheumatoid arthritis and lupus, as well as blood cancers, including non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, and diffuse large B-cell lymphoma. Additionally, the rising need for targeted immunomodulatory therapies that have fewer side effects than conventional treatments is driving investment and innovation in this field.
B-CELL INHIBITORS MARKET FOR NON-ONCOLOGY DISEASES: KEY INSIGHTS
The report delves into the current state of the B-cell inhibitors market for non-oncology diseases and identifies potential growth opportunities within industry. Some key findings from the report include:
1. The current market landscape is fragmented, featuring the presence of both established players and new entrants; of these, 36% of B-Cell inhibitors are being developed by very large companies.
2. Majority of the B cell inhibitors are presently being evaluated under phase II of clinical development; 50% of the inhibitors can be administered orally.
3. A decent increase in the number of registered clinical trials has been observed in recent years; most of the trials evaluating B-cell inhibitors have been sponsored by industry players.
4. The patent filing activity suggests that various industry and non-industry players are striving to safeguard their innovations within the B-cell inhibitors domain.
5. The rising interest in this domain is also reflected by the number of partnerships that have been inked in the recent past, involving both international and local stakeholders.
6. Assessment of the key drivers and barriers in the B-cell inhibitors market provides valuable insights to stakeholders, allowing them to enhance their offerings to adapt to the evolving needs.
7. The overall opportunity within B-cell inhibitors market is anticipated to be well distributed across various key geographies, stage of development and indication.
8. The B-cell inhibitors market in North America is expected to capture maximum share in the current year; further, close to 60% of the companies in this domain are offering inhibitors for multiple sclerosis.
9. Driven by the rising prevalence of autoimmune disorders and focus on targeted therapy development, the B-cell inhibitors market in the US is expected to grow at CAGR of 9.0%, during the forecast period.
B -CELL INHIBITORS MARKET FOR NON-ONCOLOGY DISEASES: KEY SEGMENTS
Marketed Sub-Segment Holds the Largest Market Share in the B-cell Inhibitors Market for Non-oncology Diseases
In terms of stage of development, the B-cell inhibitors market for non-oncology diseases is distributed across phase II, phase III and marketed. In the current year, the marketed sub-segment occupies the highest market share (over 80%), owing to the strong presence of B-cell Inhibitors, such as rituximab and ibrutinib. These inhibitors are known to cater to multiple indications, thus leading to expansion in their market reach. The market for B-cell Inhibitors in phase III is likely to witness a significant growth rate (CAGR) of 43% during the forecast period. This is because of the rising prevalence of autoimmune disorders across different countries.
Multiple Sclerosis Sub-Segment Holds the Largest B-cell Inhibitors Market for Non-oncology Diseases Share
In terms of indication, the B-cell inhibitors market for non-oncology diseases is distributed across ANCA, Graves' disease, hidradenitis suppurativa, immune thrombocytopenia, immunoglobulin nephropathy, membranous nephropathy, multiple sclerosis, myasthenia gravis, neuromyelitis optica, rheumatoid arthritis, sickle cell anemia, systemic lupus erythematosus, warm autoimmune hemolytic anemia. In the current year, the multiple sclerosis sub-segment holds the largest market share. This is due to the fact that multiple inhibitors have received approval for this indication across different regions. Some of these approved drugs include alemtuzumab, baricitinib, belimumab and ocrelizumab. Further, we anticipate the market to witness a substantial increase in the share of immunoglobulin nephropathy sub-segment, growing at a CAGR of 34% during the forecast period. This is because several B-cell Inhibitors are currently in the later stages of development and are likely to receive approval in the coming year.
North America Constitutes the Largest B-cell Inhibitors Market for Non-oncology Diseases Share
According to the B-cell inhibitors market for non-oncology diseases share analysis, North America is likely to capture the majority (~75%) of the B-cell Inhibitors Market for Non-oncology Diseases share in the current year. This is because North America has developed advanced healthcare infrastructure that allows developers to carry out extensive clinical trials to collect data for regulatory approval. It is worth highlighting that the market in China is likely to have higher B-cell Inhibitors Market for Non-oncology Diseases growth rate (15%). This is due to the rapidly growing patient population, the rising incidence of various indications in this country.
Example Players in the B-cell Inhibitors Market for Non-oncology Diseases
- AbbVie
- Amgen
- Bristol-Myers Squibb
- Celon Pharma
- Eli Lilly and Company
- Genentech
- GlaxoSmithKline
- Janssen Biotech
- KeyMed Biosciences
- Kiniksa Pharmaceuticals
- Novartis
- Otsuka Pharmaceuticals
- Pfizer
- RemeGen
- Rigel Pharmaceuticals
- Roche
- Sanofi
- TG Therapeutics
- Vertex Pharmaceuticals
- Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the B-cell inhibitors market for non-oncology diseases, focusing on key market segments, including [A] stage of development, [B] indication, and [C] geographical regions.
- Market Landscape: provides a detailed assessment of the B-cell inhibitor developers based on several relevant parameters, such as [A] stage of development, [B] type of molecule, [C] mechanism of action, [D] biological targets, [E] route of administration, [F] therapeutic area , [G] year of establishment, [H] company size, and [I] location of headquarters.
- Company Profiles: In-depth profiles of prominent players across North America, Europe and Asia-Pacific, focusing on [A] year of establishment, [B] location of headquarters, [C] B-Cell inhibitors portfolio, [D] recent developments and [E] an informed future outlook.
- Porter’s Five Forces Analysis: A qualitative analysis, highlighting the five competitive forces prevalent in the B-cell Inhibitors Market for Non-oncology Diseases, including [A] threats for new entrants, [B] bargaining power of drug developers, [C] bargaining power of manufacturers, [D] threats of substitute technologies and [E] rivalry among existing competitors.
- Clinical Trial Analysis: An in-depth analysis of completed and ongoing clinical trials investigating different B-Cell inhibitors, based on several relevant parameters, such as [A] trial registration year, [B] trial status, [C] trial phase, [D] patients enrolled, [E] study design [F] type of sponsor / collaborator, [G] most active industry players and [H] geographical distribution.
- Patent Analysis: An in-depth analysis of various patents that have been filed / granted for B-cell inhibitors, taking into consideration parameters, such as [A] publication year, [B] type of patent, [C] application year, [D] patent jurisdiction, [E] leading individual assignees.
- Market Impact Analysis: An in-depth analysis of the factors that can impact the growth of the B-cell Inhibitors Market for Non-oncology Diseases. It also features identification and market analysis of [A] key drivers, [B] potential restraints, [C] emerging opportunities, and [D] existing challenges
- How many companies are currently engaged in this market?
- Which are the leading companies in this market?
- What is the current global capacity of developers?
- What factors are likely to influence the evolution of this market?
- What is the current and future market size?
- What is the CAGR of this market?
- How is the current and future market opportunity likely to be distributed across key market segments?
- The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
- Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
- The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.
- Complimentary Excel Data Packs for all Analytical Modules in the Report
- 15% Free Content Customization
- Detailed Report Walkthrough Session with Research Team
- Free Updated report if the report is 6-12 months old or older
Table of Contents
402 Pages
- 1. Preface
- 1.1. Introduction
- 1.2. Market Share Insights
- 1.3. Key Market Insights
- 1.4. Report Coverage
- 1.5. Key Questions Answered
- 1.6. Chapter Outlines
- 2. Research Methodology
- 2.1. Chapter Overview
- 2.2. Research Assumptions
- 2.2.1. Market Landscape And Market Trends
- 2.2.2. Market Forecast And Opportunity Analysis
- 2.2.3. Comparative Analysis
- 2.3. Database Building
- 2.3.1. Data Collection
- 2.3.2. Data Validation
- 2.3.3. Data Analysis
- 2.4. Project Methodology
- 2.4.1. Secondary Research
- 2.4.1.1. Annual Reports
- 2.4.1.2. Academic Research Papers
- 2.4.1.3. Company Websites
- 2.4.1.4. Investor Presentations
- 2.4.1.5. Regulatory Filings
- 2.4.1.6. White Papers
- 2.4.1.7. Industry Publications
- 2.4.1.8. Conferences And Seminars
- 2.4.1.9. Government Portals
- 2.4.1.10. Media And Press Releases
- 2.4.1.11. Newsletters
- 2.4.1.12. Industry Databases
- 2.4.1.13. Roots Proprietary Databases
- 2.4.1.14. Paid Databases And Sources
- 2.4.1.15. Social Media Portals
- 2.4.1.16. Other Secondary Sources
- 2.4.2. Primary Research
- 2.4.2.1. Types Of Primary Research
- 2.4.2.1.1. Qualitative Research
- 2.4.2.1.2. Quantitative Research
- 2.4.2.1.3. Hybrid Approach
- 2.4.2.2. Advantages Of Primary Research
- 2.4.2.3. Techniques For Primary Research
- 2.4.2.3.1. Interviews
- 2.4.2.3.2. Surveys
- 2.4.2.3.3. Focus Groups
- 2.4.2.3.4. Observational Research
- 2.4.2.3.5. Social Media Interactions
- 2.4.2.4. Key Opinion Leaders Considered In Primary Research
- 2.4.2.4.1. Company Executives (Cxos)
- 2.4.2.4.2. Board Of Directors
- 2.4.2.4.3. Company Presidents And Vice Presidents
- 2.4.2.4.4. Research And Development Heads
- 2.4.2.4.5. Technical Experts
- 2.4.2.4.6. Subject Matter Experts
- 2.4.2.4.7. Scientists
- 2.4.2.4.8. Doctors And Other Healthcare Providers
- 2.4.2.5. Ethics And Integrity
- 2.4.2.5.1. Research Ethics
- 2.4.2.5.2. Data Integrity
- 2.4.3. Analytical Tools And Databases
- 2.5. Robust Quality Control
- 3. Market Dynamics
- 3.1. Chapter Overview
- 3.2. Forecast Methodology
- 3.2.1. Top-down Approach
- 3.2.2. Bottom-up Approach
- 3.2.3. Hybrid Approach
- 3.3. Market Assessment Framework
- 3.3.1. Total Addressable Market (Tam)
- 3.3.2. Serviceable Addressable Market (Sam)
- 3.3.3. Serviceable Obtainable Market (Som)
- 3.3.4. Currently Acquired Market (Cam)
- 3.4. Forecasting Tools And Techniques
- 3.4.1. Qualitative Forecasting
- 3.4.2. Correlation
- 3.4.3. Regression
- 3.4.4. Extrapolation
- 3.4.5. Convergence
- 3.4.6. Sensitivity Analysis
- 3.4.7. Scenario Planning
- 3.4.8. Data Visualization
- 3.4.9. Time Series Analysis
- 3.4.10. Forecast Error Analysis
- 3.5. Key Considerations
- 3.5.1. Demographics
- 3.5.2. Government Regulations
- 3.5.3. Reimbursement Scenarios
- 3.5.4. Market Access
- 3.5.5. Supply Chain
- 3.5.6. Industry Consolidation
- 3.5.7. Pandemic / Unforeseen Disruptions Impact
- 3.6. Limitations
- 4. Macro-economic Indicators
- 4.1. Chapter Overview
- 4.2. Market Dynamics
- 4.2.1. Time Period
- 4.2.1.1. Historical Trends
- 4.2.1.2. Current And Forecasted Estimates
- 4.2.2. Currency Coverage
- 4.2.2.1. Major Currencies Affecting The Market
- 4.2.2.2. Factors Affecting Currency Fluctuations
- 4.2.2.3. Impact Of Currency Fluctuations On The Industry
- 4.2.3. Foreign Currency Exchange Rate
- 4.2.3.1. Impact Of Foreign Exchange Rate Volatility On The Market
- 4.2.3.2. Strategies For Mitigating Foreign Exchange Risk
- 4.2.4. Recession
- 4.2.4.1. Assessment Of Current Economic Conditions And Potential Impact On The Market
- 4.2.4.2. Historical Analysis Of Past Recessions And Lessons Learnt
- 4.2.5. Inflation
- 4.2.5.1. Measurement And Analysis Of Inflationary Pressures In The Economy
- 4.2.5.2. Potential Impact Of Inflation On The Market Evolution
- 4.2.6. Interest Rates
- 4.2.6.1. Interest Rates And Their Impact On The Market
- 4.2.6.2. Strategies For Managing Interest Rate Risk
- 4.2.7. Commodity Flow Analysis
- 4.2.7.1. Type Of Commodity
- 4.2.7.2. Origins And Destinations
- 4.2.7.3. Values And Weights
- 4.2.7.4. Modes Of Transportation
- 4.2.8. Global Trade Dynamics
- 4.2.8.1. Import Scenario
- 4.2.8.2. Export Scenario
- 4.2.8.3. Trade Policies
- 4.2.8.4. Strategies For Mitigating The Risks Associated With Trade Barriers
- 4.2.8.5. Impact Of Trade Barriers On The Market
- 4.2.9. War Impact Analysis
- 4.2.9.1. Russian-ukraine War
- 4.2.9.2. Israel-hamas War
- 4.2.10. Covid Impact / Related Factors
- 4.2.10.1. Global Economic Impact
- 4.2.10.2. Industry-specific Impact
- 4.2.10.3. Government Response And Stimulus Measures
- 4.2.10.4. Future Outlook And Adaptation Strategies
- 4.2.11. Other Indicators
- 4.2.11.1. Fiscal Policy
- 4.2.11.2. Consumer Spending
- 4.2.11.3. Gross Domestic Product
- 4.2.11.4. Employment
- 4.2.11.5. Taxes
- 4.2.11.6. Stock Market Performance
- 4.2.11.7. Cross Border Dynamics
- 4.3. Conclusion
- 5. Executive Summary
- 6. Introduction
- 6.1. Chapter Overview
- 6.2. Overview Of B-cell Inhibitors
- 6.3. Types Of B-cell Inhibitors
- 6.4. Mechanism Of B-cell Inhibitors
- 6.5. B-cell Development, Activation And Differentiation
- 6.6. B-cell Receptor (Bcr) Structure And Function
- 6.7. Key Signaling Pathways And Immune Regulation
- 6.8. Limitations Of B-cell Inhibitors
- 6.9. Future Perspective
- 7. B-cell Inhibitors: Market Landscape
- 7.1. Chapter Overview
- 7.2. B-cell Inhibitors: Overall Market Landscape
- 7.2.1. Analysis By Year Of Establishment
- 7.2.2. Analysis By Company Size
- 7.2.3. Analysis By Location Of Headquarters
- 7.2.4. Analysis By Stage Of Development
- 7.2.5. Analysis By Type Of Molecule
- 7.2.6. Analysis By Route Of Administration
- 7.2.7. Analysis By Therapeutic Area
- 8. B-cell Inhibitor Developers Based In North America
- 8.1. Chapter Overview
- 8.2. Abbvie
- 8.2.1. Company Overview
- 8.2.2. Financial Information
- 8.2.3. B-cell Inhibitors Portfolio
- 8.2.4. Recent Developments And Future Outlook
- 8.3. Amgen
- 8.3.1. Company Overview
- 8.3.2. Financial Information
- 8.3.3. B-cell Inhibitors Portfolio
- 8.3.4. Recent Developments And Future Outlook
- 8.4. Bristol-myers Squibb
- 8.4.1. Company Overview
- 8.4.2. Financial Information
- 8.4.3. B-cell Inhibitors Portfolio
- 8.4.4. Recent Developments And Future Outlook
- 8.5. Genentech
- 8.5.1. Company Overview
- 8.5.2. Financial Information
- 8.5.3. B-cell Inhibitors Portfolio
- 8.5.4. Recent Development And Future Outlook
- 9. B-cell Inhibitor Developers Based In Europe
- 9.1. Chapter Overview
- 9.2. Novartis
- 9.2.1. Company Overview
- 9.2.2. Financial Information
- 9.2.3. B-cell Inhibitors Portfolio
- 9.2.4. Recent Developments And Future Outlook
- 9.3. Roche
- 9.3.1. Company Overview
- 9.3.2. Financial Information
- 9.3.3. B-cell Inhibitors Portfolio
- 9.3.4. Recent Developments And Future Outlook
- 9.4. Sanofi
- 9.4.1. Company Overview
- 9.4.2. Financial Information
- 9.4.3. B-cell Inhibitors Portfolio
- 9.4.4. Recent Developments And Future Outlook
- 10. B-cell Inhibitor Developers Based In Asia-pacific
- 10.1. Chapter Overview
- 10.2. Remegen
- 10.2.1. Company Overview
- 10.2.2. Financial Information
- 10.2.3. B-cell Inhibitors Portfolio
- 10.2.4. Recent Developments And Future Outlook
- 11. Porter’s Five Forces Analysis
- 11.1. Chapter Overview
- 11.2. Methodology And Assumptions
- 11.3. Key Parameters
- 11.3.1. Threat Of New Entrants
- 11.3.2. Bargaining Power Of Developers
- 11.3.3. Bargaining Power Of Buyers
- 11.3.4. Threat Of Substitute Products
- 11.3.5. Rivalry Among Existing Competitors
- 11.4. Porter’s Five Force Analysis: Harvey Ball Analysis
- 11.5. Concluding Remarks
- 12. Clinical Trial Analysis
- 12.1. Chapter Overview
- 12.2. Scope And Methodology
- 12.3. B-cell Inhibitors: Clinical Trial Analysis
- 12.3.1. Analysis By Trial Registration Year
- 12.3.2. Analysis Of Number Of Patients Enrolled By Trial Registration Year
- 12.3.3. Analysis By Trial Phase
- 12.3.4. Analysis Of Number Of Patients Enrolled By Trial Phase
- 12.3.5. Analysis By Trial Status
- 12.3.6. Analysis By Trial Registration Year And Trial Status
- 12.3.7. Analysis Of Number Of Patients Enrolled By Trial Status
- 12.3.8. Analysis By Patient Gender
- 12.3.9. Analysis By Study Design
- 12.3.9.1. Analysis By Type Of Allocation
- 12.3.9.2. Analysis By Type Of Intervention Model
- 12.3.9.3. Analysis By Type Of Masking
- 12.3.9.4. Analysis By Trial Purpose
- 12.3.10. Analysis By Type Of Sponsor / Collaborator
- 12.3.11. Leading Industry Players: Analysis By Number Of Clinical Trials
- 12.3.12. Leading Non-industry Players: Analysis By Number Of Clinical Trials
- 12.3.13. Analysis By Geography
- 12.3.13.1. Analysis Of Clinical Trials By Geography
- 12.3.13.2. Analysis Of Clinical Trials By Geography And Trial Status
- 12.3.13.3. Analysis Of Patients Enrolled By Geography And Trial Status
- 13. Patent Analysis
- 13.1. Chapter Overview
- 13.2. Scope And Methodology
- 13.3. B-cell Inhibitors: Patent Analysis
- 13.3.1. Analysis By Patent Publication Year
- 13.3.2. Analysis By Type Of Patent And Publication Year
- 13.3.3. Analysis By Patent Application Year
- 13.3.4. Analysis By Patent Jurisdiction
- 13.3.5. Analysis By Cpc Symbols
- 13.3.6. Analysis By Type Of Applicant
- 13.3.7. Leading Industry Players: Analysis By Number Of Patents
- 13.3.8. Leading Non-industry Players: Analysis By Number Of Patents
- 13.4. Patent Benchmarking Analysis
- 13.4.1. Analysis By Patent Characteristics
- 13.5. Patent Valuation
- 13.6. Leading Patents By Number Of Citations
- 14. Partnerships And Collaborations
- 14.1. Chapter Overview
- 14.2. Partnership Models
- 14.3. B-cell Inhibitors Market For Non-oncology Diseases: Partnerships And Collaborations
- 14.3.1. Analysis By Year Of Partnership
- 14.3.2. Analysis By Type Of Partnership
- 14.3.3. Analysis By Year And Type Of Partnership
- 14.3.4. Analysis By Type Of Partner
- 14.3.5. Most Active Players: Analysis By Number Of Partnerships
- 14.3.6. Analysis By Geography
- 14.3.6.1. Analysis By Country
- 14.3.6.2. Analysis By Continent
- 15. Market Impact Analysis
- 15.1. Chapter Overview
- 15.2. Market Drivers
- 15.3. Market Restraints
- 15.4. Market Opportunities
- 15.5. Market Challenges
- 16. Global B-cell Inhibitors Market For Non-oncology Diseases
- 16.1. Chapter Overview
- 16.2. Key Assumptions And Methodology
- 16.3 Global B-cell Inhibitors Market For Non-oncology Diseases: Historical Trends (Since 2023) And Forecasted Estimates (Till 2035)
- 16.3.1. Scenario Analysis
- 16.3.1.1. Conservative Scenario
- 16.3.1.2. Optimistic Scenario
- 16.4. Key Market Segmentations
- 17. B-cell Inhibitors Market For Non-oncology Diseases, By Stage Of Development
- 17.1. Chapter Overview
- 17.2. Key Assumptions And Methodology
- 17.3. B-cell Inhibitors Market For Non-oncology Diseases: Distribution By Stage Of Development
- 17.3.1. Phase Ii: Historical Trends (Since 2023) And Forecasted Estimates (Till 2035)
- 17.3.2. Phase Iii: Historical Trends (Since 2023) And Forecasted Estimates (Till 2035)
- 17.3.4. Marketed: Historical Trends (Since 2023) And Forecasted Estimates (Till 2035)
- 17.4. Data Triangulation And Validation
- 18. B-cell Inhibitors Market For Non-oncology Diseases, By Type Of Indication
- 18.1. Chapter Overview
- 18.2. Key Assumptions And Methodology
- 18.3. B-cell Inhibitors Market For Non-oncology Diseases: Distribution By Type Of Indication
- 18.3.1. Anca: Historical Trends (Since 2023) And Forecasted Estimates (Till 2035)
- 18.3.2. Graves' Disease: Historical Trends (Since 2023) And Forecasted Estimates (Till 2035)
- 18.3.3. Hidradenitis Suppurativa: Historical Trends (Since 2023) And Forecasted Estimates (Till 2035)
- 18.3.4. Immune Thrombocytopenia: Historical Trends (Since 2023) And Forecasted Estimates (Till 2035)
- 18.3.5. Immunoglobulin Nephropathy: Historical Trends (Since 2023) And Forecasted Estimates (Till 2035)
- 18.3.6. Membranous Nephropathy: Historical Trends (Since 2023) And Forecasted Estimates (Till 2035)
- 18.3.7. Multiple Sclerosis: Historical Trends (Since 2023) And Forecasted Estimates (Till 2035)
- 18.3.8. Myasthenia Gravis: Historical Trends (Since 2023) And Forecasted Estimates (Till 2035)
- 18.3.9. Neuromyelitis Optica: Historical Trends (Since 2023) And Forecasted Estimates (Till 2035)
- 18.3.10. Rheumatoid Arthritis: Historical Trends (Since 2023) And Forecasted Estimates (Till 2035)
- 18.3.11. Sickle Cell Anemia: Historical Trends (Since 2023) And Forecasted Estimates (Till 2035)
- 18.3.12. Systemic Lupus Erythematosus: Historical Trends (Since 2023) And Forecasted Estimates (Till 2035)
- 18.3.13. Warm Autoimmune Hemolytic Anemia: Historical Trends (Since 2023) And Forecasted Estimates (Till 2035)
- 18.4. Data Triangulation And Validation
- 19. B-cell Inhibitors Market For Non-oncology Diseases, By Key Geographies
- 19.1. Chapter Overview
- 19.2. Key Assumptions And Methodology
- 19.3. B-cell Inhibitors Market For Non-oncology Diseases: Distribution By Geographical Region
- 19.3.1. B-cell Inhibitors Market For Non-oncology Diseases In North America: Historical Trends (Since 2023) And Forecasted Estimates (Till 2035)
- 19.3.2. B-cell Inhibitors Market For Non-oncology Diseases In Europe: Historical Trends (Since 2023) And Forecasted Estimates (Till 2035)
- 19.3.3. B-cell Inhibitors Market For Non-oncology Diseases In Asia-pacific And Rest Of The World: Historical Trends (Since 2023) And Forecasted Estimates (Till 2035)
- 19.4. Data Triangulation And Validation
- 20. Market Opportunities Analysis: North America
- 20.1. B-cell Inhibitors Market For Non-oncology Diseases In North America: Distribution By Stage Of Development
- 20.1.1. B-cell Inhibitors Market For Non-oncology Diseases In North America For Phase Ii, Historical Trends (Since 2023) And Forecasted Estimates (Till 2035)
- 20.1.2. B-cell Inhibitors Market For Non-oncology Diseases In North America For Phase Iii, Historical Trends (Since 2023) And Forecasted Estimates (Till 2035)
- 20.1.3. B-cell Inhibitors Market For Non-oncology Diseases In North America For Marketed, Historical Trends (Since 2023) And Forecasted Estimates (Till 2035)
- 20.2. B-cell Inhibitors Market For Non-oncology Diseases In North America: Distribution By Indication
- 20.2.1. B-cell Inhibitors Market For Non-oncology Diseases In North America For Anca, Historical Trends (Since 2023) And Forecasted Estimates (Till 2035)
- 20.2.2. B-cell Inhibitors Market For Non-oncology Diseases In North America For Graves' Disease, Historical Trends (Since 2023) And Forecasted Estimates (Till 2035)
- 20.2.3. B-cell Inhibitors Market For Non-oncology Diseases In North America For Hidradenitis Suppurativa, Historical Trends (Since 2023) And Forecasted Estimates (Till 2035)
- 20.2.4. B-cell Inhibitors Market For Non-oncology Diseases In North America For Immune Thrombocytopenia, Historical Trends (Since 2023) And Forecasted Estimates (Till 2035)
- 20.2.5. B-cell Inhibitors Market For Non-oncology Diseases In North America For Immunoglobulin Nephropathy, Historical Trends (Since 2023) And Forecasted Estimates (Till 2035)
- 20.2.6. B-cell Inhibitors Market For Non-oncology Diseases In North America For Membranous Nephropathy, Historical Trends (Since 2023) And Forecasted Estimates (Till 2035)
- 20.2.7. B-cell Inhibitors Market For Non-oncology Diseases In North America For Multiple Sclerosis, Historical Trends (Since 2023) And Forecasted Estimates (Till 2035)
- 20.2.8. B-cell Inhibitors Market For Non-oncology Diseases In North America For Myasthenia Gravis, Historical Trends (Since 2023) And Forecasted Estimates (Till 2035)
- 20.2.9. B-cell Inhibitors Market For Non-oncology Diseases In North America For Neuromyelitis Optica, Historical Trends (Since 2023) And Forecasted Estimates (Till 2035)
- 20.2.10. B-cell Inhibitors Market For Non-oncology Diseases In North America For Rheumatoid Arthritis, Historical Trends (Since 2023) And Forecasted Estimates (Till 2035)
- 20.2.11. B-cell Inhibitors Market For Non-oncology Diseases In North America For Sickle Cell Anemia, Historical Trends (Since 2023) And Forecasted Estimates (Till 2035)
- 20.2.12. B-cell Inhibitors Market For Non-oncology Diseases In North America For Systemic Lupus Erythematosus, Historical Trends (Since 2023) And Forecasted Estimates (Till 2035)
- 20.2.13. B-cell Inhibitors Market For Non-oncology Diseases In North America For Warm Autoimmune Hemolytic Anemia, Historical Trends (Since 2023) And Forecasted Estimates (Till 2035)
- 21. Market Opportunities Analysis: Europe
- 21.1. B-cell Inhibitors Market For Non-oncology Diseases In Europe: Distribution By Stage Of Development
- 21.1.1. B-cell Inhibitors Market For Non-oncology Diseases In Europe For Phase Ii, Historical Trends (Since 2023) And Forecasted Estimates (Till 2035)
- 21.1.2. B-cell Inhibitors Market For Non-oncology Diseases In Europe For Phase Iii, Historical Trends (Since 2023) And Forecasted Estimates (Till 2035)
- 21.1.3. B-cell Inhibitors Market For Non-oncology Diseases In Europe For Marketed, Historical Trends (Since 2023) And Forecasted Estimates (Till 2035)
- 21.2. B-cell Inhibitors Market For Non-oncology Diseases In Europe: Distribution By Indication
- 21.2.1. B-cell Inhibitors Market For Non-oncology Diseases In Europe For Anca, Historical Trends (Since 2023) And Forecasted Estimates (Till 2035)
- 21.2.2. B-cell Inhibitors Market For Non-oncology Diseases In Europe For Graves' Disease, Historical Trends (Since 2023) And Forecasted Estimates (Till 2035)
- 21.2.3. B-cell Inhibitors Market For Non-oncology Diseases In Europe For Hidradenitis Suppurativa, Historical Trends (Since 2023) And Forecasted Estimates (Till 2035)
- 21.2.4. B-cell Inhibitors Market For Non-oncology Diseases In Europe For Immune Thrombocytopenia, Historical Trends (Since 2023) And Forecasted Estimates (Till 2035)
- 21.2.5. B-cell Inhibitors Market For Non-oncology Diseases In Europe For Immunoglobulin Nephropathy, Historical Trends (Since 2023) And Forecasted Estimates (Till 2035)
- 21.2.6. B-cell Inhibitors Market For Non-oncology Diseases In Europe For Membranous Nephropathy, Historical Trends (Since 2023) And Forecasted Estimates (Till 2035)
- 21.2.7. B-cell Inhibitors Market For Non-oncology Diseases In Europe For Multiple Sclerosis, Historical Trends (Since 2023) And Forecasted Estimates (Till 2035)
- 21.2.8. B-cell Inhibitors Market For Non-oncology Diseases In Europe For Myasthenia Gravis, Historical Trends (Since 2023) And Forecasted Estimates (Till 2035)
- 21.2.9. B-cell Inhibitors Market For Non-oncology Diseases In Europe For Neuromyelitis Optica, Historical Trends (Since 2023) And Forecasted Estimates (Till 2035)
- 21.2.10. B-cell Inhibitors Market For Non-oncology Diseases In Europe For Rheumatoid Arthritis, Historical Trends (Since 2023) And Forecasted Estimates (Till 2035)
- 21.2.11. B-cell Inhibitors Market For Non-oncology Diseases In Europe For Sickle Cell Anemia, Historical Trends (Since 2023) And Forecasted Estimates (Till 2035)
- 21.2.12. B-cell Inhibitors Market For Non-oncology Diseases In Europe For Systemic Lupus Erythematosus, Historical Trends (Since 2023) And Forecasted Estimates (Till 2035)
- 21.2.13. B-cell Inhibitors Market For Non-oncology Diseases In Europe For Warm Autoimmune Hemolytic Anemia, Historical Trends (Since 2023) And Forecasted Estimates (Till 2035)
- 22. Market Opportunities Analysis: Asia-pacific And Rest Of The World
- 22.1. B-cell Inhibitors Market For Non-oncology Diseases In Asia-pacific And Rest Of The World: Distribution By Stage Of Development
- 22.1.1. B-cell Inhibitors Market For Non-oncology Diseases In Asia-pacific And Rest Of The World For Phase Ii, Historical Trends (Since 2023) And Forecasted Estimates (Till 2035)
- 22.1.2. B-cell Inhibitors Market For Non-oncology Diseases In Asia-pacific And Rest Of The World For Phase Iii, Historical Trends (Since 2023) And Forecasted Estimates (Till 2035)
- 22.1.3. B-cell Inhibitors Market For Non-oncology Diseases In Asia-pacific And Rest Of The World For Marketed, Historical Trends (Since 2023) And Forecasted Estimates (Till 2035)
- 22.2. B-cell Inhibitors Market For Non-oncology Diseases In Asia-pacific And Rest Of The World: Distribution By Indication
- 22.2.1. B-cell Inhibitors Market For Non-oncology Diseases In Asia-pacific And Rest Of The World For Anca, Historical Trends (Since 2023) And Forecasted Estimates (Till 2035)
- 22.2.2. B-cell Inhibitors Market For Non-oncology Diseases In Asia-pacific And Rest Of The World For Graves' Disease, Historical Trends (Since 2023) And Forecasted Estimates (Till 2035)
- 22.2.3. B-cell Inhibitors Market For Non-oncology Diseases In Asia-pacific And Rest Of The World For Hidradenitis Suppurativa, Historical Trends (Since 2023) And Forecasted Estimates (Till 2035)
- 22.2.4. B-cell Inhibitors Market For Non-oncology Diseases In Asia-pacific And Rest Of The World For Immune Thrombocytopenia, Historical Trends (Since 2023) And Forecasted Estimates (Till 2035)
- 22.2.5. B-cell Inhibitors Market For Non-oncology Diseases In Asia-pacific And Rest Of The World For Immunoglobulin Nephropathy, Historical Trends (Since 2023) And Forecasted Estimates (Till 2035)
- 22.2.6. B-cell Inhibitors Market For Non-oncology Diseases In Asia-pacific And Rest Of The World For Membranous Nephropathy, Historical Trends (Since 2023) And Forecasted Estimates (Till 2035)
- 22.2.7. B-cell Inhibitors Market For Non-oncology Diseases In Asia-pacific And Rest Of The World For Multiple Sclerosis, Historical Trends (Since 2023) And Forecasted Estimates (Till 2035)
- 22.2.8. B-cell Inhibitors Market For Non-oncology Diseases In Asia-pacific And Rest Of The World For Myasthenia Gravis, Historical Trends (Since 2023) And Forecasted Estimates (Till 2035)
- 22.2.9. B-cell Inhibitors Market For Non-oncology Diseases In Asia-pacific And Rest Of The World For Neuromyelitis Optica, Historical Trends (Since 2023) And Forecasted Estimates (Till 2035)
- 22.2.10. B-cell Inhibitors Market For Non-oncology Diseases In Asia-pacific And Rest Of The World For Rheumatoid Arthritis, Historical Trends (Since 2023) And Forecasted Estimates (Till 2035)
- 22.2.11. B-cell Inhibitors Market For Non-oncology Diseases In Asia-pacific And Rest Of The World For Sickle Cell Anemia, Historical Trends (Since 2023) And Forecasted Estimates (Till 2035)
- 22.2.12. B-cell Inhibitors Market For Non-oncology Diseases In Asia-pacific And Rest Of The World For Systemic Lupus Erythematosus, Historical Trends (Since 2023) And Forecasted Estimates (Till 2035)
- 22.2.13. B-cell Inhibitors Market For Non-oncology Diseases In Asia-pacific And Rest Of The World For Warm Autoimmune Hemolytic Anemia, Historical Trends (Since 2023) And Forecasted Estimates (Till 2035)
- 23. Concluding Remarks
- 24. Appendix I: Tabulated Data
- 25. Appendix Ii: List Of Companies And Organizations
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.